4D Molecular Therapeutics FDMT Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by 4D Molecular Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The official record: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about 4D Molecular Therapeutics's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is 4D Molecular Therapeutics's retained earnings?
- 4D Molecular Therapeutics (FDMT) reported retained earnings of -$785.06M in Q1 2026.
- How has 4D Molecular Therapeutics's retained earnings changed year-over-year?
- 4D Molecular Therapeutics's retained earnings decreased by 25.8% year-over-year, from -$624.17M to -$785.06M.
- What is the long-term trend for 4D Molecular Therapeutics's retained earnings?
- Over 5 years (2020 to 2025), 4D Molecular Therapeutics's retained earnings has grown at a 39.5% compound annual growth rate (CAGR), from -$135.68M to -$716.3M.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.